Clinical trials: COVID-19-Induced Parosmia
Anosmia, Hyposmia
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Chronic olfactory dysfunction from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the Unites States affected.
- Conditions
- Anosmia, Hyposmia, Parosmia, Olfactory Disorder
- Trial name
- NCT05445921
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
COVID-19
The Effect of Olfactory Training in Patients With COVID-19 Induced Olfactory Dysfunction
Aim: The aim is to investigate the effect of olfactory training with essential oils versus olfactory training with placebo-oils in patients with COVID-19 induced olfactory dysfunction Study design: The study is a…
- Trial name
- SMELLT2022 (NCT05539560)
- Testing
- Olfactory training with essential oils, Olfactory training with fragrance-free oils
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Ditte Gertz Mogensen
COVID-19-Induced Parosmia
Stellate Ganglion Block for COVID-induced Parosmia
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected.
- Trial name
- SGB (NCT06253806)
- Testing
- Stellate Ganglion Block
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Parosmia
Stellate Ganglion Block With Lidocaine for the Treatment of COVID-19-Induced Parosmia
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis, affecting up to 1.2 million people in the United States.
- Trial name
- Stella (NCT06055270)
- Testing
- Stellate Ganglion Block
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's